A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM)

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Journal of Neuro-Oncology

• Publication date

  2009-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11060-008-9741-zPMID 19018475
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma

  2008cited by this paper
• Randomized phase II trial of erlotinib (E) versus temozolomide (TMZ) or BCNU in recurrent glioblastoma multiforme (GBM): EORTC 26034

  2007cited by this paper
• Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours.

  2006cited by this paper
• Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma.

  2006cited by this paper
• Phase 1 Trial of Gefitinib Plus Sirolimus in Adults with Recurrent Malignant Glioma

  2006cited by this paper
• Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas

  2006cited by this paper
• mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt.

  2006cited by this paper
• A phase I/II trial of RAD 001 with gefitinib in patients with castrate metastatic prostate cancer and glioblastoma multiforme.

  2006cited by this paper
• Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

  2005cited by this paper
• Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.

  2005cited by this paper
• Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.

  2005cited by this paper
• Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme

  2005cited by this paper
• Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition.

  2005cited by this paper
• mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma.

  2005cited by this paper
• Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

  2005cited by this paper
• Dose-Dependent Effects of Platelet-Derived Growth Factor-B on Glial Tumorigenesis

  2004cited by this paper
• Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin

  2004cited by this paper
• Phase II trial of gefitinib in recurrent glioblastoma.

  2004cited by this paper
• Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo.

  2003cited by this paper
• Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.

  2003cited by this paper
• Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

  2002cited by this paper
• Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR) ‐dependent signaling

  2002cited by this paper
• The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner.

  2002cited by this paper
• Regulation of Hypoxia-Inducible Factor 1α Expression and Function by the Mammalian Target of Rapamycin

  2002cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• Epidermal growth factor-related peptides and their receptors in human malignancies.

  1995cited by this paper

• Nanosystems at Nexus: Navigating Nose-to-Brain Delivery for Glioblastoma Treatment.

  2025cites this paper
• The safety and efficacy of tyrosine kinase inhibitors against EGFR in patients with glioma; A systematic review, meta-analysis, and sub-group analysis on glioblastoma.

  2025cites this paper
• Targeting Glioma Stem Cells: Therapeutic Opportunities and Challenges

  2025cites this paper
• Challenges and advances in glioblastoma targeted therapy: the promise of drug repurposing and biomarker exploration

  2024cites this paper
• Autophagic-Related Proteins in Brain Gliomas: Role, Mechanisms, and Targeting Agents

  2023cites this paper
• From signalling pathways to targeted therapies: unravelling glioblastoma’s secrets and harnessing two decades of progress

  2023cites this paper
• SEM1 promotes tumor progression of glioblastoma via activating the akt signaling pathway.

  2023cites this paper
• Orthotopic Glioblastoma Models for Evaluation of the Clinical Target Volume Concept

  2022cites this paper
• The impact of different volumetric thresholds to determine progressive disease in patients with recurrent glioblastoma treated with bevacizumab

  2022cites this paper
• Targeting BCAT1 combined with α-ketoglutarate triggers metabolic synthetic lethality in glioblastoma.

  2022cites this paper
• Prognosis and Immune Landscapes in Glioblastoma Based on Gene-Signature Related to Reactive-Oxygen-Species

  2022cites this paper
• Thymoquinone induces apoptosis in temozolomide‐resistant glioblastoma cells via the p38 mitogen‐activated protein kinase signaling pathway

  2022cites this paper
• Current and promising treatment strategies in glioma

  2022cites this paper
• Glioblastoma Multiforme (GBM): An overview of current therapies and mechanisms of resistance.

  2021cites this paper
• Therapeutic strategies of recurrent glioblastoma and its molecular pathways ‘Lock up the beast’

  2021cites this paper
• Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma.

  2021cites this paper
• Disentangling the signaling pathways of mTOR complexes, mTORC1 and mTORC2, as a therapeutic target in glioblastoma.

  2021cites this paper
• Afatinib and radiotherapy, with or without temozolomide, in patients with newly diagnosed glioblastoma: results of a phase I trial

  2021cites this paper
• N6-Isopentenyladenosine Hinders the Vasculogenic Mimicry in Human Glioblastoma Cells through Src-120 Catenin Pathway Modulation and RhoA Activity Inhibition

  2021cites this paper
• Autophagy as a Potential Therapy for Malignant Glioma

  2020cites this paper
• Use of Gefitinib in EGFR-Amplified Refractory Solid Tumors: An Open-Label, Single-Arm, Single-Center Prospective Pilot Study

  2020cites this paper
• Familial/inherited cancer syndrome: a focus on the highly consanguineous Arab population

  2020cites this paper
• A high-throughput drug combination screen identifies an anti-glioma synergism between MTH1 and PI3K inhibitors

  2020cites this paper
• Innovative therapies for malignant brain tumors: the road to a tailored cure

  2020cites this paper
• The impact of autophagy during the development and survival of glioblastoma

  2020cites this paper
• Novel Treatment Strategies for Glioblastoma

  2020cites this paper
• Reduced EGFR and increased miR-221 is associated with increased resistance to temozolomide and radiotherapy in glioblastoma

  2020cites this paper
• Novel approaches to combat chemoresistance against glioblastomas

  2020cites this paper
• A high-throughput drug combination screen identifies an anti-glioma synergism between TH588 and PI3K inhibitors

  2020cites this paper
• Innovative Therapeutic Approaches to Fight Glioblastoma

  2019cites this paper
• Precise Immunodetection of PTEN Protein in Human Neoplasia.

  2019cites this paper
• Diverse signaling mechanisms of mTOR complexes: mTORC1 and mTORC2 in forming a formidable relationship.

  2019cites this paper
• Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.

  2019cites this paper
• Autophagic and Apoptotic Pathways as Targets for Chemotherapy in Glioblastoma

  2018cites this paper
• Evidence and context of use for contrast enhancement as a surrogate of disease burden and treatment response in malignant glioma

  2018cites this paper
• mTOR inhibition in glioblastoma: requiem for a dream?

  2018cites this paper
• Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial

  2018cites this paper
• Gene Fusion in Malignant Glioma: An Emerging Target for Next-Generation Personalized Treatment

  2018cites this paper
• Immunogenetics of glioblastoma: the future of personalized patient management

  2018cites this paper
• EGFR as a clinical marker in glioblastomas and other gliomas

  2018cites this paper
• New Multitarget Approaches in the War Against Glioblastoma: A Mini-Perspective

  2018cites this paper
• First-in-human immunomodulation mechanism research of chlorogenic acid in patients with recurrent high-grade glioma

  2018cites this paper
• Glioblastoma therapeutic challenge : preventing and treating tumor recurrence

  2017cites this paper
• Overcoming therapeutic resistance in glioblastoma: the way forward.

  2017cites this paper
• Contemporary management of high-grade gliomas

  2017cites this paper
• Exploiting Genetic Vulnerabilities to Overcome Treatment Resistance in Adult Gliomas

  2017cites this paper
• tumor infiltrating lymphocytes in glioblastoma Running title : PD-L 1 expression in glioblastoma

  2017influential citation
• Phase II trial of dacomitinib, a pan–human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification

  2017cites this paper
• Glioblastoma targeted therapy: updated approaches from recent biological insights

  2017cites this paper
• Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study

  2017cites this paper
• Probing the phosphatidylinositol 3‐kinase/mammalian target of rapamycin pathway in gliomas: A phase 2 study of everolimus for recurrent adult low‐grade gliomas

  2017cites this paper
• Suppression of invasion-driving RGS 4 by radiation-enhanced mTOR inhibition optimizes antiangiogenesis

  2017cites this paper
• Antibody–drug conjugates in glioblastoma therapy: the right drugs to the right cells

  2017cites this paper
• Inhibiting 4EBP1 in Glioblastoma

  2017cites this paper
• Advances in Biology and Treatment of Glioblastoma

  2017cites this paper
• Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.

  2017cites this paper
• Recent Advances for Targeted Therapies in Glioblastoma

  2017cites this paper
• Cell Signaling Pathways in Brain Tumors

  2017cites this paper
• Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects.

  2017cites this paper
• Targeting Aberrant Signaling Pathways

  2017cites this paper
• Chapter 5 – Multimodality Targeting of Glioma Cells

  2016cites this paper
• Pharmacotherapies for the treatment of glioblastoma – current evidence and perspectives

  2016cites this paper
• From Molecular to Clinical Radiation Biology of Glioblastoma

  2016cites this paper
• Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives

  2016cites this paper
• Radiobiological Hints from Clinical Studies

  2016cites this paper
• The mTOR signalling cascade: paving new roads to cure neurological disease

  2016cites this paper
• Suppression of long-circulating and liposomes containing gefitinibon nasopharyngeal carcinoma cells

  2016cites this paper
• Stimulation of prolactin receptor induces STAT-5 phosphorylation and cellular invasion in glioblastoma multiforme

  2016cites this paper
• PI3K–mTOR Pathway Inhibition Exhibits Efficacy Against High-grade Glioma in Clinically Relevant Mouse Models

  2016cites this paper
• Precision medicine in glioblastoma therapy

  2016cites this paper
• Thérapies par rayonnements appliquées au cas du glioblastome : Intérêt du suivi par spectroscopie et imagerie de diffusion par résonance magnétique.Vers une thérapie bimodale.

  2016cites this paper
• Therapeutic options in recurrent glioblastoma--An update.

  2016cites this paper
• Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)

  2016cites this paper
• Conditions associated with increased growth hormone and prolactin sensitivity

  2016cites this paper
• Chapter 11 – Recurrent Glioblastoma

  2016cites this paper
• Targeting Oncoproteins for Molecular Cancer Therapy

  2016cites this paper
• Biomarkers for glioblastoma multiforme: status quo

  2016cites this paper
• Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma.

  2015cites this paper
• Toward precision medicine in glioblastoma: the promise and the challenges.

  2015influential citation
• METABOLOMICS AND PROTEOMICS STUDIES OF BRAIN TUMORS - A CHEMOMETRIC BIOINFORMATICS APPROACH

  2015cites this paper
• Combination Therapy of Intraperitoneal Rapamycin and Convection- Enhanced Delivery of Nanoliposomal CPT-11 in Rodent Orthotopic Brain Tumor Xenografts.

  2015cites this paper
• Nanomedicine to overcome radioresistance in glioblastoma stem-like cells and surviving clones.

  2015cites this paper
• Genomic discoveries in adult astrocytoma.

  2015cites this paper
• Plasma and cerebrospinal fluid pharmacokinetics of the Akt inhibitor, perifosine, in a non-human primate model

  2015cites this paper
• Novel chemotherapeutic approaches in adult high-grade gliomas.

  2015cites this paper
• Everolimus combined with gefitinib in patients with metastatic castration‐resistant prostate cancer: Phase 1/2 results and signaling pathway implications

  2015influential citation
• The Challenges and the Promise of Molecular Targeted Therapy in Malignant Gliomas1

  2015cites this paper
• Adult High-Grade (Diffuse) Glioma

  2015cites this paper
• Genetic Characteristics of Glioblastoma: Clinical Implications of Heterogeneity

  2015cites this paper
• Targeted Therapy in Solid Tumors: Brain

  2015cites this paper
• Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date

  2015cites this paper
• Targeted Therapy in Gliomas

  2014cites this paper
• Influence of active efflux transport on the distribution of targeted agents to brain tumors

  2014influential citation
• Molecularly targeted therapies for recurrent glioblastoma: current and future targets.

  2014cites this paper
• Challenges to targeting epidermal growth factor receptor in glioblastoma: escape mechanisms and combinatorial treatment strategies.

  2014cites this paper
• PI3K pathway inhibitors: potential prospects as adjuncts to vaccine immunotherapy for glioblastoma.

  2014cites this paper
• Prognosis in human glioblastoma based on expression of ligand growth hormone-releasing hormone, pituitary-type growth hormone-releasing hormone receptor, its splicing variant receptors, EGF receptor and PTEN genes

  2014cites this paper
• Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.

  2014cites this paper
• A critical evaluation of PI3K inhibition in Glioblastoma and Neuroblastoma therapy

  2014cites this paper
• Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma.

  2014cites this paper